{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:07:13Z","timestamp":1782976033559,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ad.2016.03.004","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T14:23:01Z","timestamp":1461939781000},"page":"498-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["An\u00e1lisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis act\u00ednica en Espa\u00f1a"],"prefix":"10.1016","volume":"107","author":[{"given":"I.","family":"El\u00edas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ortega-Joaqu\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"del Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Moreno-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mirada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Oyag\u00fcez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2016.03.004_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000366525","article-title":"Epidemiology of actinic keratoses","volume":"46","author":"Green","year":"2015","journal-title":"Curr Probl Dermatol."},{"key":"10.1016\/j.ad.2016.03.004_bib0175","first-page":"599","article-title":"Guidelines for the management of actinic keratoses","volume":"16","author":"Stockfleth","year":"2006","journal-title":"Eur J Dermatol."},{"key":"10.1016\/j.ad.2016.03.004_bib0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/annonc\/mdh032","article-title":"Cancer of the skin: A forgotten problem in Europe","volume":"15","author":"Boyle","year":"2004","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ad.2016.03.004_bib0185","unstructured":"Ferr\u00e1ndiz Foraster C. Prevalence of actinic keratosis in Spain. Estudio epidemiol\u00f3gico EPIQA: Prevalencia de queratosis act\u00ednica en servicios generales de dermatolog\u00eda hospitalarios espa\u00f1oles. [Comunicaci\u00f3n Oral]. Primer Simposio Internacional sobre C\u00e1ncer de Piel. Madrid, 30-31 de enero de 2015 [consultado Nov 2015]. Disponible en: http:\/\/www.sbc-congresos.com\/pdf2015\/Programa-preliminar-SKINCANCER.pdf"},{"key":"10.1016\/j.ad.2016.03.004_bib0190","unstructured":"Werner RN. Systematic review of the natural course of actinic keratosis and their relation to squamous cell carcinoma. Berlin: Aus der Division of Evidence based Medicine (dEBM) der Klinik f\u00fcr Dermatologie, Venerologie und Allergologie, Medizinische Fakultt\u00e4 Charit\u00e9-Universit\u00e4tsmedizin Berlin; 2014."},{"key":"10.1016\/j.ad.2016.03.004_bib0195","doi-asserted-by":"crossref","first-page":"888","DOI":"10.6004\/jnccn.2010.0066","article-title":"The economic impact of non-melanoma skin cancer: A review","volume":"8","author":"Mudigonda","year":"2010","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.ad.2016.03.004_bib0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000366530","article-title":"Patients\u2019 perspectives on actinic keratosis","volume":"46","author":"Esmann","year":"2015","journal-title":"Curr Probl Dermatol."},{"key":"10.1016\/j.ad.2016.03.004_bib0205","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jdv.13180","article-title":"Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version","volume":"29","author":"Werner","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2016.03.004_bib0210","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ad.2013.11.013","article-title":"Adaptaci\u00f3n espa\u00f1ola de la Gu\u00eda europea para la evaluaci\u00f3n y tratamiento de la queratosis act\u00ednica","volume":"105","author":"Ferr\u00e1ndiz","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2016.03.004_bib0215","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2006.07692.x","article-title":"Guidelines for the management of actinic keratoses","volume":"156","author":"De Berker","year":"2007","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2016.03.004_bib0220","unstructured":"Instituto Nacional de Estad\u00edstica (INE) [consultado Mar 2015]. Disponible en: http:\/\/www.ine.es\/"},{"key":"10.1016\/j.ad.2016.03.004_bib0225","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","volume":"24","author":"L\u00f3pez Bastida","year":"2010","journal-title":"Gac Sanit."},{"key":"10.1016\/j.ad.2016.03.004_bib0230","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2016.03.004_bib0235","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","article-title":"Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: Histological and clinical study results","volume":"165","author":"Stockfleth","year":"2011","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2016.03.004_bib0240","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.ad.2016.03.004_bib0245","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2016.03.004_bib0250","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.ad.2016.03.004_bib0255","unstructured":"Ficha t\u00e9cnica imiquimod [consultado Mar 2015]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000179\/WC500023122.pdf"},{"key":"10.1016\/j.ad.2016.03.004_bib0260","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11538670-000000000-00000","article-title":"Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: A decision tree model","volume":"28","author":"Wilson","year":"2010","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.ad.2016.03.004_bib0265","unstructured":"Bot PLUS 2.0 [consultado Mar 2015]. Disponible en: https:\/\/botplusweb.portalfarma.com\/botplus.aspx"},{"key":"10.1016\/j.ad.2016.03.004_bib0270","unstructured":"Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. BOE n\u00fam. 126 de 24 de mayo de 2010 [consultado Mar 2015]. Disponible en: http:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010-8228.pdf"},{"key":"10.1016\/j.ad.2016.03.004_bib0275","unstructured":"Oblikue Consulting. eSalud. Informaci\u00f3n econ\u00f3mica del sector sanitario [consultado Mar 2015]. Disponible en: http:\/\/www.oblikue.com\/bddcostes\/"},{"key":"10.1016\/j.ad.2016.03.004_bib0280","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","article-title":"\u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a?","volume":"16","author":"Sacrist\u00e1n","year":"2002","journal-title":"Gac Sanit."},{"key":"10.1016\/j.ad.2016.03.004_bib0285","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10198-011-0326-y","article-title":"The use of cost per life year gained as a measurement of cost-effectiveness in Spain: A systematic review of recent publications","volume":"13","author":"Rodr\u00edguez Barrios","year":"2012","journal-title":"Eur J Health Econ."},{"key":"10.1016\/j.ad.2016.03.004_bib0290","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.ad.2015.04.010","article-title":"Clinical response to ingenol mebutate in patients with actinic keratoses","volume":"106","author":"Batalla","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2016.03.004_bib0295","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ad.2015.04.014","article-title":"Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: A pilot study","volume":"106","author":"Jubert-Esteve","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2016.03.004_bib0300","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/14737167.2015.995171","article-title":"Cost-effectiveness analysis of 5-fluorouracil 0.5%\/salicylic acid 10% in the treatment of actinic keratosis in Spain","volume":"15","author":"Nieves","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"10.1016\/j.ad.2016.03.004_bib0305","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10198-015-0679-8","article-title":"A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective","volume":"17","author":"Tolley","year":"2016","journal-title":"Eur J Health Econ."},{"key":"10.1016\/j.ad.2016.03.004_bib0310","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12325-015-0211-7","article-title":"Cost-utility of first-line actinic keratosis treatments in Finland","volume":"32","author":"Soini","year":"2015","journal-title":"Adv Ther."},{"key":"10.1016\/j.ad.2016.03.004_bib0315","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.ad.2016.03.004_bib0320","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ."},{"key":"10.1016\/j.ad.2016.03.004_bib0325","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health."},{"key":"10.1016\/j.ad.2016.03.004_bib0330","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","article-title":"A single European currency for EQ-5D health states. Results from a six-country study","volume":"4","author":"Greiner","year":"2003","journal-title":"Eur J Health Econ."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173101630028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173101630028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:05:12Z","timestamp":1757552712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000173101630028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S000173101630028X"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2016.03.004","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An\u00e1lisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis act\u00ednica en Espa\u00f1a","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2016.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}